Description

Prolia (denosumab) solution for injections 60 mg/ml. syringe 1ml

Ingredients

Prolia contains the active ingredient denosumab at a concentration of 60 mg/ml in a 1ml syringe.

Dosage

Prolia is typically administered as a subcutaneous injection of 60 mg once every 6 months.

Indications

Prolia is indicated for the treatment of osteoporosis in postmenopausal women and in men at increased risk of fractures.

Contraindications

Prolia should not be used in patients with hypocalcemia or a history of hypocalcemia.

Directions

Prolia should be administered by a healthcare professional as a subcutaneous injection in the upper arm, upper thigh, or abdomen.

Scientific Evidence

Studies have shown that denosumab effectively increases bone mineral density and reduces the risk of fractures in postmenopausal women with osteoporosis. Research published in the New England Journal of Medicine demonstrated a significant reduction in vertebral, nonvertebral, and hip fractures with the use of Prolia.

Additional Information

It is important to monitor serum calcium levels in patients receiving Prolia and to ensure an adequate intake of calcium and vitamin D. Regular follow-up with a healthcare provider is essential to assess treatment response and address any potential side effects.

Prolia works by inhibiting bone resorption and increasing bone mass, leading to improved bone strength and reduced fracture risk. This mechanism of action differs from other osteoporosis medications, offering a unique treatment option for patients.

Comparative studies have shown that denosumab is more effective in increasing bone mineral density and reducing fractures compared to bisphosphonates. The convenience of a twice-yearly dosing schedule also improves treatment adherence and outcomes for patients.